source
- J&J's IBD combo fails Phase 2 studies, but will move into pivotal testingJohnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…Endpoints · 2mo ago↗ source
- Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström MacroglobulinemiaIopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.onclive · 2mo ago↗ source
- Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCCBradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.